Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Passage Bio Inc (NQ: PASG )

0.6211 -0.0289 (-4.45%)
Streaming Delayed Price Updated: 2:53 PM EDT, Sep 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Passage Bio Inc

< Previous 1 2 Next >
Passage Bio to Present at Chardan’s 8th Annual Genetic Medicines Conference
From Passage Bio
Via GlobeNewswire
Passage Bio to Present Positive Interim Data from Cohort 1 Patients with FTD-GRN in upliFT-D Study at 14th International Conference on Frontotemporal Dementias (ISFTD2024)
From Passage Bio
Via GlobeNewswire
Passage Bio Welcomes Tom Kassberg to Board of Directors
From Passage Bio
Via GlobeNewswire
Passage Bio to Present at H.C. Wainwright 26th Annual Global Investment Conference
From Passage Bio
Via GlobeNewswire
Passage Bio Reports Second Quarter 2024 Financial Results and Provides Recent Business Highlights
From Passage Bio
Via GlobeNewswire
Passage Bio to Participate in Upcoming Investor Conferences
From Passage Bio
Via GlobeNewswire
Passage Bio Out-licenses Three Pediatric Gene Therapy Programs to GEMMA Biotherapeutics and Enters New Research Collaboration
From Passage Bio
Via GlobeNewswire
Passage Bio Announces Positive Feedback from FDA on Expansion of upliFT-D Trial of PBFT02 to Include FTD-C9orf72 Patients
From Passage Bio
Via GlobeNewswire
Passage Bio to Present at Goldman Sachs 45th Annual Global Healthcare Conference
From Passage Bio
Via GlobeNewswire
Passage Bio Reports First Quarter 2024 Financial Results and Provides Recent Business Highlights
From Passage Bio
Via GlobeNewswire
Passage Bio to Present at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
From Passage Bio
Via GlobeNewswire
Passage Bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Recent Business Highlights
From Passage Bio
Via GlobeNewswire
Passage Bio to Participate in Upcoming Investor Conferences
From Passage Bio
Via GlobeNewswire
Passage Bio to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
From Passage Bio
Via GlobeNewswire
Passage Bio Announces Promising Initial Data From Phase 1/2 Clinical Trial of PBFT02 in FTD-GRN and Updated Strategic Priorities
From Passage Bio
Via GlobeNewswire
Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
From Passage Bio
Via GlobeNewswire
Passage Bio Reports Third Quarter 2023 Financial Results and Provides Recent Business Highlights
From Passage Bio
Via GlobeNewswire
Passage Bio to Present at Guggenheim’s 5th Annual Inflammation, Neurology & Immunology Conference
From Passage Bio
Via GlobeNewswire
Passage Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Passage Bio
Via GlobeNewswire
Passage Bio to Present at Chardan’s 7th Annual Genetic Medicines Conference
From Passage Bio
Via GlobeNewswire
Passage Bio Reports Second Quarter 2023 Financial Results and Provides Recent Business Highlights
From Passage Bio
Via GlobeNewswire
Passage Bio Announces Promising Interim Clinical Data from First Eight Patients with GM1 Gangliosidosis in Imagine-1 Study
From Passage Bio
Via GlobeNewswire
Passage Bio to Participate in Upcoming Investor Conferences
From Passage Bio
Via GlobeNewswire
Passage Bio Welcomes Dolan Sondhi, Ph.D. to Board Of Directors
From Passage Bio
Via GlobeNewswire
Passage Bio to Present at Goldman Sachs 44th Annual Global Healthcare Conference
From Passage Bio
Via GlobeNewswire
Passage Bio Reports First Quarter 2023 Financial Results and Provides Recent Business Highlights
From Passage Bio
Via GlobeNewswire
Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Passage Bio
Via GlobeNewswire
Passage Bio to Present at Chardan’s 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
From Passage Bio
Via GlobeNewswire
Passage Bio to Present at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days
From Passage Bio
Via GlobeNewswire
Passage Bio Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Recent Business Highlights
From Passage Bio
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.